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Abstract
Schizophrenia is a complex psychiatric disorder characterized by positive symptoms, negative symptoms, and cognitive
impairment. MAGI2, a relatively large gene (,1.5 Mbps) that maps to chromosome 7q21, is involved in recruitment of
neurotransmitter receptors such as AMPA- and NMDA-type glutamate receptors. A genetic association study designed to
evaluate the association between MAGI2 and cognitive performance or schizophrenia has not been conducted. In this case-
control study, we examined the relationship of single nucleotide polymorphism (SNP) variations in MAGI2 and risk for
schizophrenia in a large Japanese sample and explored the potential relationships between variations in MAGI2 and aspects
of human cognitive function related to glutamate activity. Based on the result of first schizophrenia genome-wide
association study in a Japanese population (JGWAS), we selected four independent SNPs and performed an association
study using a large independent Japanese sample set (cases 1624, controls 1621). Wisconsin Card Sorting Test (WCST) was
used to evaluate executive function in 114 cases and 91 controls. We found suggestive evidence for genetic association of
common SNPs within MAGI2 locus and schizophrenia in Japanese population. Furthermore in terms of association between
MAGI2 and cognitive performance, we observed that genotype effect of rs2190665 on WCST score was significant (p=0.034)
and rs4729938 trended toward significance (p=0.08). In conclusion, although we could not detect strong genetic evidence
for association of common variants in MAGI2 and increased schizophrenia risk in a Japanese population, these SNPs may
increase risk of cognitive impairment in schizophrenic patients.
Citation: Koide T, Banno M, Aleksic B, Yamashita S, Kikuchi T, et al. (2012) Common Variants in MAGI2 Gene Are Associated with Increased Risk for Cognitive
Impairment in Schizophrenic Patients. PLoS ONE 7(5): e36836. doi:10.1371/journal.pone.0036836
Editor: Chuhsing Kate Hsiao, National Taiwan University, Taiwan
Received November 20, 2011; Accepted April 7, 2012; Published May 23, 2012
Copyright:  2012 Koide et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for this study was provided by research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (http://www.
mext.go.jp/english/); The Ministry of Health, Labor and Welfare of Japan (http://www.mhlw.go.jp/english/); Grant-in-Aid for ‘‘Integrated research on
neuropsychiatric disorder’’ carried out under the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and
Technology of Japan (http://brainprogram.mext.go.jp/); Grant-in-Aid for Scientific Research on Innovative Areas (Comprehensive Brain Science Network) from the
Ministry of Education, Science, Sports and Culture of Japan (https://www.hokatsu-nou.nips.ac.jp/); The Academic Frontier Project for Private Universities,
Comparative Cognitive Science Institutes (http://www.meijo-u.ac.jp/sougou/gakujutsu/hitech.html); and the Core Research for Evolutional Science and
Technology (http://www.jst.go.jp/kisoken/crest/en/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: branko@med.nagoya-u.ac.jp
Introduction
Schizophrenia is a complex psychiatric disorder, affecting
approximately 1% of the general population. It is characterized
by positive symptoms, negative symptoms, and cognitive
impairment. The heritability of schizophrenia is estimated to
be 64% [1]. Although genes relevant for schizophrenia or
variants that may modulate risk for the disease have been
identified using both linkage- and candidate-based or whole
genome association studies, the genetic basis of schizophrenia is
still unclear [2,3,4,5].
Considerable evidence supports a relationship between cogni-
tive impairment and functional outcome in schizophrenia [6].
Cognitive impairment is considered a core feature of schizophre-
nia that includes problems is processing speed, attention/vigilance,
working memory, verbal learning, visual learning, problem
solving, and social cognition. The molecular mechanisms respon-
sible for cognitive deficits in schizophrenia are to some extent
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components involved are synaptic scaffolding molecules of the
membrane-associated guanylate kinase (MAGUK) family, such as
PSD-95 and PSD-93 [8]. Closely related to the MAGUK family of
scaffolding molecules are the inverted MAGUKs (MAGIs).
Mammalian MAGIs are found at both synapses and epithelial
junctions [9]. However only MAGI2 (also called synaptic
scaffolding molecule, or S-SCAM) is brain-specific [10] and has
been shown to interact with NMDA receptors at excitatory
synapses [9].
Human MAGI2 is relatively large gene (,1.5 Mbps) that maps
to chromosome 7q21. Interestingly, recent copy number variation
analyses have identified deletions in gene coding MAGI2 in
schizophrenia [11]. MAGI2 is also interesting from a biological
point of view. One study showed that MAGI2 is involved in
recruitment of neurotransmitter receptors such as AMPA- and
NMDA-type glutamate receptors [12]. MAGI2 is present at
glutamatergic synapses, where it interacts with NMDA receptors,
neuroligin1, and b-catenin and at GABAergic synapses, it has
been reported that MAGI2 can interact with b-dystroglycan and
neuroligin2, suggesting that this scaffold molecule may provide a
link between the DGC and the neurexin–neuroligin adhesion
system [13]. Moreover, in Caenorhabditis elegans, mutation in magi-1
(a close homolog of mammalian MAGI2 proteins) leads to deficits
in neuron-specific regulation of associative learning and memory
[14], while complete deletion of magi-1 is associated with the
experience-dependent regulation of subunit-specific AMPAR
trafficking and behavioral plasticity as well as defects in long-term
memory acquisition in vivo [15].
To the best of our knowledge, no genetic association study
specifically designed to evaluate the association between MAGI2
and cognitive performance or schizophrenia has been conducted.
However, several weak association signals (p,0.05) within the
MAGI2 locus were detected in the first genome-wide association
study of schizophrenia conducted in a Japanese population
(JGWAS) [16]. It is of note that in this JGWAS, no genome-
wide evidence for an association was detected, and the non-
genome-wide level of statistical significance should be interpreted
with caution. However, due to the relatively small sample size, a
type II error (false-negative result) cannot be excluded [17],
especially in cases of small odds ratios (OR), which are expected
for common single nucleotide polymorphisms (SNPs) associated
with schizophrenia.
In this study, we examined the relationship of SNP variations in
MAGI2 and the risk for schizophrenia in a large Japanese case-
control sample and also explored potential relationships between
variations in MAGI2 and aspects of human cognitive function
related to glutamate activity. We reasoned that if MAGI2 increases
the risk for psychosis by virtue of its putative role as an indirect
modulator of NMDA neurotransmission, it should also impact
cognitive function associated with NMDA signaling, which has
also been associated with psychosis.
Results
Association Study
In the confirmation sample set, no SNPs showed a p value less
than 0.05. HWE p values in controls were not significant. In the
joint analysis, two SNPs showed p values less than 0.05
(rs2190665: p=0.0033, odds ratio of minor allele 0.88,
rs4729938: p=0.027, odds ratio of minor allele 1.11) (Table 1).
The calculated threshold by the SNPSpD was at p=0.125
(Supplementary Methods S1) [18].
Population Stratification Analysis
Using HapMap data, we confirmed that CEU, YRI, CHB, and
JPT were divided into three ethnic clusters (Figure S2). Using
HapMap data of CEU and YRI and representatives of our
confirmation sample from 105 randomly selected cases and
controls, we also confirmed three ethnic clusters (Figure S3).
There was no obvious population stratification between cases and
controls in our confirmation sample set (Figure S4). Our results
thus should not be considered a false-positive association that was
simply caused by population stratification.
Cognitive Function Analysis
We investigated genetic effects of rs2190665 and rs4729938 on
WCST. Results are shown in Figure 1. There was no significant
difference in clinical information between two groups divided by
genotypes of rs2190665 and rs4729938 in cases and controls
(Table S1).
In terms of rs2190665, the WCST score was significantly better
in the G (protective allele) carrier group (p=0.034) in cases. In
controls, there was no significant cognitive difference between two
groups. In terms of rs4729938, the WCST score was worse in the
G (risk allele) carrier group in cases, although this value did not
reach statistical significance (p=0.08).
Discussion
In this study, we investigated the association between 4 SNPs
within MAGI2 and schizophrenia in the Japanese population. We
detected suggestive evidence of associations between MAGI2 and
schizophrenia in the joint analysis; however, as the JGWAS
dataset was included in the joint analysis, evidence for association
might be overestimated. To address this issue, we tested the
association between candidate SNPs from our joint analysis and
cognitive performance measured by WCST. This analysis was of
interest for us as MAGI2 is indirect modulator of NMDA
neurotransmission and may impact cognitive function associated
with NMDA signaling. Therefore if the two SNPs (rs2190665 and
rs4729938) were genuinely associated with schizophrenia, then
carriers of risk alleles would likely have deficits in cognitive
processing assessed by WCST, as the central executive function is
often impaired in schizophrenic patients [19,20]. All participants
in this study were of Japanese descent and recruited from the
central area of Japan. We confirmed the lack of stratification
within our cases and controls in this study by genotyping and
analyzing 98 independent SNPs using our confirmation sample set
(Figures S2, S3 and S4). Our association study and cognitive
function analysis may be more accurate than research using
genomes from people living in the Europe or the United States
using the same sample size.
There were several important findings in our study. First, we
showed that two SNPs (rs2190665 and rs4729938) may be
associated with schizophrenia. Due to the gene length and coarse
LD pattern of MAGI2, it has been difficult to conduct association
studies covering the whole MAGI2 region without using GWAS
results as a screening set. One SNP (rs2190665) is located in intron
and the G allele may be a protective allele with an odds ratio of
0.88. The other SNP (rs4729938) is located about 9560 base pairs
after MAGI2, and the G allele may be a risk allele with an odds
ratio of 1.11, and the possibility of false-positive findings due to
population stratification seems to be low. Furthermore, we
investigated the association between two SNPs and cognitive
performance in cases and controls. We could observe significant
difference between C/C and G carrier groups of rs2190665 in
terms of cognitive performance measured by WCST. The G
MAGI2 and Cognitive Impairment in Schizophrenia
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than the C/C group. In the control group, there were no
significant differences in rs2190665 between the C/C and G
carrier groups. This SNP may not be associated with cognitive
performance in controls. The G (risk allele) carrier group of
rs4729938 in cases had lower WCST scores, although differences
Table 1. Results of association study and joint analysis.
Number SNP Confirmation sample (n=3245) OR
2 L95 U95 HWEp




2 L95 U95 P_BD
4
1 rs2190665 0.39 0.42 0.06 0.91 0.82 1.01 0.79 0.0033 0.88 0.80 0.96 0.22
2 rs10260177 0.04 0.04 0.39 1.12 0.87 1.44 0.49 0.44 0.92 0.74 1.14 0.003
3 rs2215379 0.21 0.21 0.85 1.01 0.89 1.15 0.88 0.18 0.93 0.84 1.03 0.01
4 rs4729938 0.32 0.31 0.33 1.06 0.95 1.18 0.72 0.027 1.11 1.01 1.22 0.08
1Fisher’s exact test.
2Odds ratio.
3Hardy–Weinberg equilibrium p-value in controls.
4Breslow-Day test p-value.
doi:10.1371/journal.pone.0036836.t001
Figure 1. Wisconsin Card Sorting Test composite scores. rs2190665: C allele is risk allele, rs4729938:G allele is risk allele.
doi:10.1371/journal.pone.0036836.g001
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increase the sample size, we might detect significant difference
between C/C group and G carrier groups for rs4729938 in cases.
In contrast, we did not find any significant differences between the
C/C and G carrier group for rs4729938 in the control group. This
SNP may not be associated with cognitive performance in
controls.
Several limitations should be considered when interpreting the
results of our study. First, in terms of sample size, the replication
dataset may not have sufficient statistical power to detect
associations between SNPs with low genotype relative risk
(GRR) and schizophrenia. In other words, our sample has
statistical power greater than 0.8 for the detection of association
signals at nominal statistical significance, of the polymorphism
with a minor allele frequency of 0.05, when the GRR is 1.30.
Therefore, the possibility of association between the schizophrenia
and common SNPs with a GRR ,1.30 cannot be excluded.
Furthermore, the JGWAS may not have sufficient power to detect
associations between SNPs with low GRR and schizophrenia.
Therefore, other relevant common variants in the MAGI2 region,
which the JGWAS cannot identify, may exist.
The second limitation is that our study design was based on the
common disease, common variant hypothesis, based on which we
applied a minor allele frequency threshold (.5%) and selected
four SNPs for follow up. In the best case scenario, common
variants detected in GWAS can explain only part of the
heritability in cases of schizophrenia (,30%) [4] and missense
or nonsense mutations on the one side and structural variations
(i.e., copy number variants) on the other side are likely to
contribute to the increased susceptibility [21]. Recently, the
concept of synthetic associations has been suggested, though some
objections exist [22]. Uncommon or rare genetic variants can
easily create synthetic associations that are credited to common
variants. This possibility requires careful consideration in the
interpretation and follow up of GWAS signals [23].
The third limitation is that cases and controls in replication
samples were not matched in terms of age in our association study.
In other words, although highly unlikely, the controls may develop
schizophrenia at some point in life, as they were significantly
younger than cases.
The fourth limitation is about significant level in our association
study. We used JGWAS dataset as a prioritization tool to greatly
reduce numbers of candidate SNPs. In joint analysis, three of four
association signals with p,0.05 obtained might not survive the
statistical significance threshold after multiple comparisons using
the Bonferroni correction or the SNPSpD (Supplementary
Methods S1) [18]. In addition, the possibility of inflation of p-
value of JGWAS results might affect the results in joint analysis,
thus the genetic evidence from this study should be regarded as
suggestive.
The fifth limitation is about the WCST. The WCST has been
used to estimate executive function in schizophrenia, however,
several studies have indicated that WCST performance was
mainly influenced by individual specific environmental variance
rather than genetic variance [24,25,26]. Other cognitive tests that
are not be susceptible to the environmental influence would be
useful for evaluation of the further relationship between MAGI2
and cognitive function.
In conclusion, common variants in MAGI2 selected based on
JGWAS findings, may be associated with increased schizophrenia
risk in a Japanese population. Moreover, we have provided
evidence that common SNPs in the MAGI2 gene region increase
risk of cognitive impairment in schizophrenia. The nature of this
impairment is consistent with findings from a variety of studies of
NMDA-based signaling cascades in excitatory neurotransmission.
In particular, executive function became progressively more
compromised with increased ‘risk allele load’. Our results thus
extend findings for the role for MAGI2 in serious neuropsychiatric
conditions by suggesting that a mutation in MAGI2 may be present




This study was approved by the Ethics Committees of the
Nagoya University Graduate School of Medicine and associated
institutes and hospitals. Written informed consent was obtained
from all participants. In addition, the patients’ capacity to consent
was confirmed by the family member when needed. Subjects with
legal measure of reduced capacity were excluded. Patients were
included in the study if they (1) met DSM-IV criteria for
schizophrenia, (2) were physically healthy and (3) had no mood
disorders, substance abuse, neurodevelopmental disorders, epilep-
sy or known mental retardation. A general characterization and
psychiatric assessment of subjects is available elsewhere [16].
Controls were selected from the general population. Control
subjects had no history of mental disorders, based on questionnaire
responses from the subjects themselves during the sample inclusion
step, and based on an unstructured diagnostic interview done by
an experienced psychiatrist during the blood collection step.
The JGWAS sample was comprised of 575 patients with
schizophrenia (43.5614.8 years (mean6s.d.), male 50%) and 564
healthy controls with no personal or family history of psychiatric
illness (44.0614.4 years (mean6s.d.), male 49.8%). All subjects
were unrelated, living in the central area of the Honshu island of
Japan and self-identified as members of the Japanese population.
For SNP association analysis, we used an independent Japanese
sample set (confirmation sample) comprising 1624 cases (aged
46.5614.5 years, male 50.6%) and 1621 controls (aged 45.1614.0
years, male 49.0%). For analysis of cognitive performance, we
investigated 114 cases (aged 44.9613.5 years, male 60.5%) and 91
controls (aged 24.966.17 years, male 64.8%).
SNP Prioritization Step
To reduce the number of candidate SNPs for genotyping (due to
the length of MAGI2) we used the JGWAS dataset as a
prioritization tool. All SNPs that were represented on Affymetrix
5.0 array (Affymetrix, Santa Clara, CA) across the MAGI2 gene
and 5% upstream and downstream were selected. A total of 348
SNPs were in this region. Of those, 32 were monomorphic, 80
were excluded due to the low minor allele frequency in controls
(,5%), 8 had genotyping call rates ,90%, and 7 had significant
deviation from Hardy-Weinberg equilibrium (HWE) (p,0.001).
257 SNPs were included in further analyses. The candidate SNPs
were defined based on a statistical significance level of p,0.01.
Highly correlated markers based on r
2.0.8 to a more significant
marker within 100 kb (r
2 was based on HapMap information
[release 24] and our own GWAS from controls) were then
removed. Finally we selected 4 nonredundant SNPs within the
MAGI2 locus (Table 2). Linkage disequilibrium (LD) structure of
the MAGI2 region, allelic p values of each SNP in JGWAS, and
positions of the four selected SNPs are shown in Figure 2. The LD
structure of the four SNPs is shown in Figure S1. All four SNPs
were intronic polymorphisms. We investigated the function of
these 4 SNPs and other SNPs within the LD of these 4 SNPs, using
SNP function prediction (http://snpinfo.niehs.nih.gov/snpfunc.
MAGI2 and Cognitive Impairment in Schizophrenia
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(Table S2).
Genotyping and Data Analysis
DNA was extracted from peripheral blood according to
standard protocols [28]. Genotyping was performed using a
fluorescence-based allelic discrimination assay (Taqman, Applied
Biosystems, Foster City, CA). To exclude low-quality DNA
samples or genotyping probes, data sets were filtered on the basis
of SNP genotype call rates (95% completeness) or deviation from
the HWE (p,0.05) in the control sample. Subjects whose
percentage of missing genotypes was .10% or who had evidence
of possible DNA contamination were excluded from subsequent
analyses. All allele-wise association analyses (JGWAS or confir-
mation sample) were carried out by calculating the p values for
each candidate SNP. Significance was determined at the 0.05 level
using Fisher’s exact test. All p values were two-sided. To reduce
the total number of tests, clearly unassociated markers were
removed in the first stage involving the screening sample of the
present study. Next, conditional on the findings of the first stage,
which used a less stringent nominal level, was tested in the second
stage involving the confirmation sample using the augmented data
and data from the first stage. In this joint analysis, p values were
generated by Cochran-Mantel-Haenszel stratified analysis, and the
Breslow-Day test was performed for evaluation of heterogeneous
associations as implemented in PLINK v1.07 [29]. Statistical
significance was set at nominal level (p,0.05) in association study
using confirmation sample set and joint analysis. The SNPSpD
can make a simple correction for multiple testing of SNPs in LD
with each other, on the basis of the spectral decomposition (SpD)
of matrices of pairwise LD between SNPs [18]. This method is less
conservative than the Bonferroni correction. Using the program
(http://gump.qimr.edu.au/general/daleN/SNPSpD/), we calcu-
lated the adjusted p-value in our total sample set (n=4353)
including all cases and controls.
Population Stratification Analysis
To avoid false-positive associations caused by potential popu-
lation stratification, we performed population stratification analysis
on our confirmation sample set, using genotype data on 98
additional random LD independent SNPs. We obtained data on
these 98 SNPs from 638 HapMap samples (174 CEU [Utah
residents with ancestry from northern and western Europe in the
United States], 209 YRI [Yoruba in Ibadan, Nigeria], 139 CHB
[Han Chinese in Beijing], and 116 JPT [Japanese in Tokyo]) from
HapMap public release 28 at http://hapmap.ncbi.nlm.nih.gov.
First we investigated whether these SNPs worked well to
differentiate HapMap sample sets into distinct clusters according
to their ethnicity. Second we investigated whether these SNPs
worked well to differentiate confirmation sample set from non
Japanese sample set (HapMap dataset). Third we investigated
uniformity of the distribution of cases and controls from
confirmation sample within the population stratification plot using
Structure version 2.3.3 software (http://pritch.bsd.uchicago.edu/
structure.html). We applied an admixture model and an
independent allelic frequency model and ran at K=3, where K
is the number of potential classifications of tested samples. For all
Structure runs, we set the parameters with a burn-in of 10 000
iterations and 20 000 follow-on iterations.
Neurocognitive Assessment
The Wisconsin Card Sorting Test (WCST) scores were used in
this study because they (1) are known to be sensitive to the effects
of glutamate manipulations [30] and (2) are important predictors
of clinical outcome [31].
The WCST [32] mainly assesses executive function including
cognitive flexibility in response to feedback. We used a modified
and computerized version of the test: Wisconsin Card Sorting Test
(Keio Version) (KWCST) [33]. The outcome measures commonly
used in KWCST were numbers of categories achieved (CA), total
errors (TE) and perseverative errors of Milner (PEM) and Nelson
Figure 2. Linkage disequilibrium structure of MAGI2. MAF: minor




Table 2. Selected single nucleotide polymorphisms (SNPs) based on results of the Japanese genome-side association study








1 rs2190665 78322159 Intron 1 C G 0.40 0.46 0.0098 0.80 0.68 0.95
2 rs10260177 78075634 Intron 2 T C 0.03 0.05 0.0028 0.50 0.32 0.80
3 rs2215379 78050595 Intron 3 C T 0.18 0.23 0.0037 0.74 0.60 0.91
4 rs4729938 77637379 Intergenic 4 C G 0.36 0.30 0.0077 1.27 1.07 1.52
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current study because TE, PEM and PEN are highly correlated.
CA is the number of categories for which six consecutive correct
responses are achieved (eight is the maximum number of
categories that can be achieved), and is the sum measure of the
level of conceptual shifts in the KWCST. PEN is the number of
incorrect responses in the same category as the immediately
preceding incorrect response (maximum of 47 perseverative errors)
[35,36].
Clinical Information
Patients’ records were used to obtain relevant clinical informa-
tion (e.g. age, education, Chlorpromazine (CPZ) equivalent doses,
age at onset and duration of illness).
CPZ equivalent doses of antipsychotic medications were
calculated based on the report by Inagaki et al. [37,38].
Medication status of patients was investigated on the day when
cognitive tests were conducted. Patients’ medication status and
positive and negative symptom scale (PANSS) [39] scores were
obtained at the time of cognitive assessment.
Analysis of Cognitive Performance
We checked the effect of two SNPs on cognitive performance
measured by WCST within 114 schizophrenic patients and 91
healthy controls. To avoid the problem of multiple comparisons,
WCST CA and PEN scores were used to synthesize the WCST
composite score, and the first factor scores were derived from an
unrotated principal component analysis in all participants. Several
studies investigating association study and cognitive tests have
been conducted [40,41]. In these studies, unrotated principal
component analysis was used to calculate general cognitive ability
of subjects from many cognitive measures. In the current study,
calculated WCST composite scores were converted to Z-scores
using the standardized mean=0 and standard deviation=1 from
the data set of all participants, such that lower values reflect worse
performance. The first unrotated factor explained 89.7% of the
variance.
We compared Z-scores of WCST composite scores between two
groups divided by genotype, CC and G carrier groups, in cases
and controls using the student t-test. Clinical information (age,
education, CPZ equivalent doses, age at onset, duration of illness
and PANSS) of two groups divided by genotype between
schizophrenia cases and control subjects was compared using the
student t-test and Welch’s t-test. We compared sex between cases
and controls using Fisher’s exact test. IBM SPSS statistical
software, version 19 (IBM Japan, Tokyo, Japan) was used for all
analyses. All tests were two-tailed and significance was set at
p=0.05.
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